

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Simcere Pharmaceutical Group Limited**  
**先聲藥業集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 2096)**

## **UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”), together with its subsidiaries, the “**Group**”) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and at the request of the Stock Exchange.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company was aware of recent unusual movements in the price and trading volume of the shares of the Company (the “**Shares**”) on the Stock Exchange. Having made such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reasons for these share price or trading volume movements, and it is not aware of any information which must be announced to avoid a false market in the Shares or of any inside information that needs to be disclosed pursuant to the Inside Information Provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On November 17, 2021, the Company entered into a technology transfer contract with Shanghai Institute of Materia Medica, Chinese Academy of Sciences (“**SIMM**”), etc., pursuant to which the Group will obtain development, production and commercialization rights on an exclusive basis of the anti-novel coronavirus (“**SARS-CoV-2**”) drug candidate SIM0417 series worldwide. SIM0417 can replicate 3CL, a key protease essential against SARS-CoV-2 virus, and has shown good antiviral activity and safety in preclinical animal models. As this protease is highly conservative, SIM0417 shows strong inhibition against a variety of COVID-19 variants, including the highly contagious Delta variant.

## ABOUT SIMM

Founded in 1932, SIMM is the oldest comprehensive innovative drug research institute in China. Targeting the frontiers of international life science development and important scientific problems in drug research, SIMM conducts basic and applied fundamental research on innovative drugs and develops new theories, methods and technologies for drug research. In recent years, through the establishment of a comprehensive innovative drug research and development system with complete functions, advanced technology, comprehensive integration, seamless connection, efficient operation and international standards, the institute has focused on the research and development of new drugs for the treatment of malignant tumours, cardiovascular and cerebrovascular diseases, neuropsychiatric diseases, metabolic diseases, autoimmune diseases and infectious diseases. It has promoted a series of innovative drugs into clinical research as a brand name drug research entity.

This announcement is made by the order of the Company and each Director collectively and individually accepts responsibility for the accuracy of this announcement.

**The Company cannot guarantee that it will be able to successfully develop and ultimately market SIM0417. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board of  
**Sincere Pharmaceutical Group Limited**  
**Mr. Ren Jinsheng**  
*Chairman and Chief Executive Officer*

Hong Kong, November 18, 2021

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.*